Biotech company ORIG3N nabs $20 mln
Boston-based ORIG3N, a biotechnology company that is developing treatments for rare and genetically inherited diseases, has raised $20 million in funding. Hatteras Venture Partners led the round with participation from Spectrum Health Ventures, LabCorp, Syno Capital, KTB-KORUS Fund, MGC Venture Partners, DEFTA Partners and 180 Degree Capital. In conjunction with the funding, Byron Smith, a principal at Mountain Group Partners, has been added to ORIG3N's board of directors.
27 June 2017•6 mins read
